» Articles » PMID: 34495700

Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation

Overview
Journal J Virol
Date 2021 Sep 8
PMID 34495700
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The high pathogenicity of SARS-CoV-2 requires it to be handled under biosafety level 3 conditions. Consequently, Spike protein-pseudotyped vectors are a useful tool to study viral entry and its inhibition, with retroviral, lentiviral (LV), and vesicular stomatitis virus (VSV) vectors the most commonly used systems. Methods to increase the titer of such vectors commonly include concentration by ultracentrifugation and truncation of the Spike protein cytoplasmic tail. However, limited studies have examined whether such a modification also impacts the protein's function. Here, we optimized concentration methods for SARS-CoV-2 Spike-pseudotyped VSV vectors, finding that tangential flow filtration produced vectors with more consistent titers than ultracentrifugation. We also examined the impact of Spike tail truncation on transduction of various cell types and sensitivity to convalescent serum neutralization. We found that tail truncation increased Spike incorporation into both LV and VSV vectors and resulted in enhanced titers but had no impact on sensitivity to convalescent serum. In addition, we analyzed the effect of the D614G mutation, which became a dominant SARS-CoV-2 variant early in the pandemic. Our studies revealed that, similar to the tail truncation, D614G independently increases Spike incorporation and vector titers, but this effect is masked by also including the cytoplasmic tail truncation. Therefore, the use of full-length Spike protein, combined with tangential flow filtration, is recommended as a method to generate high titer pseudotyped vectors that retain native Spike protein functions. Pseudotyped viral vectors are useful tools to study the properties of viral fusion proteins, especially those from highly pathogenic viruses. The Spike protein of SARS-CoV-2 has been investigated using pseudotyped lentiviral and VSV vector systems, where truncation of its cytoplasmic tail is commonly used to enhance Spike incorporation into vectors and to increase the titers of the resulting vectors. However, our studies have shown that such effects can also mask the phenotype of the D614G mutation in the ectodomain of the protein, which was a dominant variant arising early in the COVID-19 pandemic. To better ensure the authenticity of Spike protein phenotypes when using pseudotyped vectors, we recommend using full-length Spike proteins, combined with tangential flow filtration methods of concentration if higher-titer vectors are required.

Citing Articles

Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.

Adeleke R, Sahler J, Choi A, Roth K, Upadhye V, Ezzatpour S Sci Adv. 2025; 11(5):eadq4545.

PMID: 39879304 PMC: 11777205. DOI: 10.1126/sciadv.adq4545.


SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization.

Qing E, Salgado J, Wilcox A, Gallagher T PLoS Pathog. 2024; 20(12):e1012757.

PMID: 39621785 PMC: 11637440. DOI: 10.1371/journal.ppat.1012757.


Multiplex Microscopy Assay for Assessment of Therapeutic and Serum Antibodies against Emerging Pathogens.

Sartingen N, Sturmer V, Kaltenbock M, Muller T, Schnitzler P, Kreshuk A Viruses. 2024; 16(9).

PMID: 39339949 PMC: 11437451. DOI: 10.3390/v16091473.


Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV.

Ngare I, Tan T, Toyoda M, Kuwata T, Takahama S, Nakashima E Viruses. 2024; 16(4).

PMID: 38675897 PMC: 11053946. DOI: 10.3390/v16040555.


ACE2 from bats is a receptor for HKU5 coronaviruses.

Catanzaro N, Wu Z, Fan C, Schafer A, Yount B, Bjorkman P bioRxiv. 2024; .

PMID: 38559009 PMC: 10980018. DOI: 10.1101/2024.03.13.584892.


References
1.
Masre S, Jufri N, Ibrahim F, Raub S . Classical and alternative receptors for SARS-CoV-2 therapeutic strategy. Rev Med Virol. 2020; 31(5):1-9. PMC: 7883063. DOI: 10.1002/rmv.2207. View

2.
Schmidt F, Weisblum Y, Muecksch F, Hoffmann H, Michailidis E, Lorenzi J . Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020; 217(11). PMC: 7372514. DOI: 10.1084/jem.20201181. View

3.
Aguilar H, Matreyek K, Choi D, Filone C, Young S, Lee B . Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol. 2007; 81(9):4520-32. PMC: 1900187. DOI: 10.1128/JVI.02205-06. View

4.
Starr T, Greaney A, Hilton S, Ellis D, Crawford K, Dingens A . Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020; 182(5):1295-1310.e20. PMC: 7418704. DOI: 10.1016/j.cell.2020.08.012. View

5.
Greaney A, Starr T, Gilchuk P, Zost S, Binshtein E, Loes A . Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2020; 29(1):44-57.e9. PMC: 7676316. DOI: 10.1016/j.chom.2020.11.007. View